There are no generic Brovana (arformoterol tartrate) products available in the United States at this time, despite the fact that the first two patents for the drug have already expired. This suggests that Brovana is protected by other patents, the next of which is set to expire in November 2016.
Brovana® (arformoterol tartrate) is a prescription medication used to treat chronic obstructive pulmonary disease (COPD). It is part of a class of medications known as beta-adrenergic receptor agonists, or beta agonists for short. It is a long-acting COPD medication used twice a day, every day to help prevent COPD symptoms.
Brovana is manufactured for Sunovion Pharmaceuticals, Inc. It is currently under the protection of a patent that prevents any generic Brovana from being manufactured in the United States.
The first patents for Brovana expired in April 2012 and April 2013. Yet, no generic versions became available. This suggests that other, later-expiring patents are still protecting the drug from generic competition. The next patent is set to expire in November 2016.
At this point, this is the earliest predictable date that a generic version of the medication could become available. However, there are other circumstances that could arise to extend or shorten the exclusivity period of Brovana. This could include such things as lawsuits or other patents for specific Brovana uses. Once Brovana goes off patent, there may be several companies that begin manufacturing a generic Brovana drug.
The answer is no. Arformoterol is the active ingredient in Brovana but is not a generic version of the medicine. What can be confusing is that, oftentimes, the active ingredient of any drug is referred to as the "generic name." The generic name is different from a generic version of a medicine. In order for there to be a generic version of a medicine, the original medicine must have gone off patent, and another company besides the original manufacturer must make the product.